Want to see FR:ALDVI full AI Analyst Report?
ALDVI Stock Chart & Stats
€1.72
€0.01(0.70%)
At close: 4:00 PM EST
€1.72
€0.01(0.70%)
Day’s Range― - ―
52-Week Range€0.80 - €2.35
Previous CloseN/A
Volume979.00
Average Volume (3M)26.23K
Market Cap
€20.38M
Enterprise Value€33.89M
Total Cash (Recent Filing)€1.34M
Total Debt (Recent Filing)€19.00M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Sep 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding14,609,619
10 Day Avg. Volume23,481
30 Day Avg. Volume26,231
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-0.87
Price to Sales (P/S)3.81
P/FCF Ratio-5.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)€7.20M
Bulls Say, Bears Say
Bulls Say
Niche Specialty ProductAdvicenne’s Sibnayal® is a proprietary prolonged‑release therapy for rare renal diseases, creating a focused specialty franchise. That niche positioning supports durable demand from chronic patients, potential pricing power, and limited broad-market competition where approval and reimbursement exist.
Improving Gross MarginsReported improvement from negative to positive gross margins by 2025 indicates better unit economics for the core product. Sustained positive gross profitability reduces cash burn per sale, improving the path to operational leverage as commercialization scales and supporting longer‑term viability.
Lean Operating Base (small Headcount)A headcount of 21 implies a lean cost structure and low fixed overhead. That structural lightness permits scaling commercial activity through partners or distributors with limited incremental SG&A, preserving runway and allowing more flexible allocation of resources to sales or R&D as revenues evolve.
Bears Say
Negative Equity / Stressed Balance SheetNegative equity across multiple years signals balance sheet impairment and elevated solvency risk. This constraint reduces strategic flexibility, raises the probability of dilutive capital raises or restrictive financing, and undermines the company's ability to fund growth or absorb shocks without external support.
Persistent Negative Cash FlowContinuous negative operating and free cash flow demonstrates ongoing cash burn and reliance on external funding. Although burn improved in 2024, deterioration in 2025 shows cash generation instability, threatening sustained commercialization and R&D spending absent reliable financing sources.
Small, Volatile And Declining RevenueRevenue volatility and a 2025 decline indicate fragile commercial momentum for a single‑product specialty company. For a rare‑disease therapy dependent on reimbursement and clinician adoption, inconsistent sales growth undermines predictability of future cash flows and limits the company's ability to reach scale economics.
Advicenne SA News
ALDVI FAQ
What was Advicenne SA’s price range in the past 12 months?
Advicenne SA lowest stock price was €0.80 and its highest was €2.35 in the past 12 months.
What is Advicenne SA’s market cap?
Advicenne SA’s market cap is €20.38M.
When is Advicenne SA’s upcoming earnings report date?
Advicenne SA’s upcoming earnings report date is Sep 17, 2026 which is in 73 days.
How were Advicenne SA’s earnings last quarter?
Advicenne SA released its earnings results on Mar 26, 2026. The company reported -€0.314 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.314.
Is Advicenne SA overvalued?
According to Wall Street analysts Advicenne SA’s price is currently Overvalued.
Does Advicenne SA pay dividends?
Advicenne SA does not currently pay dividends.
What is Advicenne SA’s EPS estimate?
Advicenne SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Advicenne SA have?
Advicenne SA has 14,609,619 shares outstanding.
What happened to Advicenne SA’s price movement after its last earnings report?
Advicenne SA reported an EPS of -€0.314 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.933%.
Which hedge fund is a major shareholder of Advicenne SA?
Currently, no hedge funds are holding shares in FR:ALDVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Advicenne SA
Advicenne S.A. operates as a specialized pharmaceutical firm, focusing on the innovation and commercialization of therapeutic solutions for various kidney-related disorders. The company's primary offering, Sibnayal, targets both distal renal tubular acidosis and cystinuria. Established in 2007, Advicenne S.A. maintains its principal offices in Paris, France.